Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of “Moderate Buy” by Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have earned an average rating of “Moderate Buy” from the twenty-four research firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $278.59.

ALNY has been the subject of a number of recent analyst reports. Raymond James boosted their target price on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Leerink Partners increased their price objective on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a report on Tuesday, June 25th. Stifel Nicolaus boosted their target price on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. TD Cowen raised their target price on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Finally, Barclays boosted their price target on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $262.69 on Monday. The firm has a market capitalization of $33.72 billion, a PE ratio of -98.02 and a beta of 0.37. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $287.55. The firm’s 50-day moving average is $255.96 and its two-hundred day moving average is $187.86.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. The business’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period last year, the company earned ($2.21) earnings per share. Analysts expect that Alnylam Pharmaceuticals will post -2.82 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at $20,563,480. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the firm’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the transaction, the executive vice president now directly owns 14,181 shares of the company’s stock, valued at $3,275,669.19. The disclosure for this sale can be found here. Insiders sold a total of 103,148 shares of company stock valued at $25,658,824 in the last quarter. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $26,000. Altitude Crest Partners Inc. acquired a new position in Alnylam Pharmaceuticals during the 1st quarter valued at about $30,000. Robeco Institutional Asset Management B.V. boosted its stake in shares of Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares during the last quarter. Finally, V Square Quantitative Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $52,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.